Eisai (ESAIY) and Biogen (BIIB) announced that humanized anti- soluble aggregated amyloid-beta monoclonal antibody LEQEMBI Intravenous Infusion has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease. Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
- Reata stockholders approve merger transaction with Biogen
- Jefferies biotechnology analyst to hold an analyst/industry conference call
- Reata says waiting period related to merger under Hart-Scott-Rodino act expired
- Biogen Appoints Jane Grogan as Head of Research